CureVac and Glaxo Begin Testing New ‘Second Generation’ Covid-19 Vaccine – Barron’s

CureVac and GlaxoSmithKline said Wednesday that they had dosed the first patient in the first trial of what they call their second-generation messenger RNA vaccine for Covid-19.

The companies said that the development program to test the vaccine, known as CV2CoV, will serve as a proof of concept not just for the vaccine itself, but for CureVacs (ticker: CVAC) updated mRNA technology.

CureVac...

Go here to read the rest:

CureVac and Glaxo Begin Testing New 'Second Generation' Covid-19 Vaccine - Barron's

Related Posts
Tags: